fda drug safety communication naion semaglutide 2025 Suboptimal therapeutic responses associated with in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials: Cell Reports Medicine November 2025 Drug Safety: Recalls

In NMOSD, where pathogenic anti-AQP4 antibodies drive disease, Awad et al

Results from the SELECT trial also indicated that a dose of 2.4mg of semaglutide has potential to combat kidney function decline among individuals with cardiovascular disease who are overweight or have obesity, but without diabetes

From a baseline weight of 212 pounds (96.16 kilograms), the higher doses also resulted in weight loss of between 15 pounds (6.80 kilograms) to 20 pounds (9.07 kilograms), compared to about 10 pounds (4.54 kilograms) on the lower dose

DiamondGlow offers SkinMedica Pro-Infusion Serums to complement your skin

(PubMed) Donadio JV, Grande JP

Ristoff, E., Hebert, C., Njalsson, R., Norgren, S., Rooyackers, O